Anoro Ellipta

Chemical Nameumeclidinium and vilanterol
Dosage FormPowder (oral inhalation; 62.5mcg umeclidinium and 25mcg vilanterol)
Drug ClassAnticholinergics
SystemRespiratory
CompanyGlaxoSmithKline plc
Approval Year2013

Indication

  • For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Last updated on 4/27/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Anoro Ellipta (umeclidinium and vilanterol) Prescribing Information2013GlaxoSmithKline, Research Triangle Park, NC